The Factors That May Predict Response to Rituximab Therapy in Recurrent Focal Segmental Glomerulosclerosis: A Systematic Review

Table 3

Univariate analysis for the 3-outcome model of complete, partial response, and no response, to rituximab therapy. Values expressed as median (range) or proportion (%).

Variable	Complete response (𝑛=17)	Partial response (𝑛=8)	No response (𝑛=14)	𝑃 value
Age at diagnosis (years)	5 (1–33)	7.5 (2–30)	12 (1.9–40)	0.12
Age at transplant (years)	13 (5–48)	22.5 (8–41)	30 (5.5–48)	0.07
Male gender	14/17 (82.4)	2/8 (25)	6/14 (42.8)	0.01
Time to end stage renal disease (years)	3 (0.16–19)	3 (0.6–9)	4 (0.5–12)	0.65
Time to relapse (days)	1 (1–3513)	8 (1–150)	22 (1–828)	0.12
Deceased donor source	11/17 (64.7)	6/8 (75)	10/14 (71.4)	1.00
Serum albumin at relapse (g/dL)	2.7 (1.4–4.4)	3.2 (2–4)	2.3 (1.2–3.3)	0.05
Proteinuria (g/day)	10.25 (1.1–97.4)	5.8 (2–14)	7.64 (2.4–20)	0.19
Plasmapheresis				0.43
<20 treatments	7/17 (41.2)	2/8 (25)	6/14 (42.8)
21–50 treatments	7/17 (41.2)	3/8 (37.5)	2/14 (14.4)
>50 treatments	3/17 (17.6)	3/8 (37.5)	6/14 (42.8)
Pretransplant plasmapheresis	6/17 (35.3)	1/8 (12.5)	2/14 (14.4)	0.37
Posttransplant plasmapheresis	16/17 (94.1)	8/8 (100)	14/14 (100)	1.00
Rituximab doses	2 (2–6)	3 (1–5)	4 (2–6)	0.03
Time from transplant to rituximab (days)	120 (4–3543)	343 (10–1095)	276 (65–1050)	0.08
Time from relapse to rituximab (days)	62 (3–927)	271 (9–1086)	179 (57–1048)	0.03
Diagnosis of PTLD	2/17 (11.8)	1/8 (12.5)	0/14 (0)	0.41
Cyclophosphamide use	1/17 (5.9)	1/8 (12.5)	2/14 (14.4)	0.81
Tacrolimus use	13/17 (76.5)	8/8 (100)	9/14 (64.3)	0.18
Mycophenolate mofetil use	16/17 (94.1)	8/8 (100)	13/14 (92.8)	1.00